Amgen Inc. (ETR:AMG)

Germany flag Germany · Delayed Price · Currency is EUR
252.15
-5.40 (-2.10%)
Jul 11, 2025, 5:35 PM CET
-14.76%
Market Cap 135.76B
Revenue (ttm) 31.57B
Net Income (ttm) 5.49B
Shares Out n/a
EPS (ttm) 10.12
PE Ratio 24.73
Forward PE 14.28
Dividend 8.59 (3.41%)
Ex-Dividend Date May 16, 2025
Volume 231
Average Volume 305
Open 255.55
Previous Close 257.55
Day's Range 251.60 - 256.00
52-Week Range 230.75 - 318.05
Beta 0.50
RSI 53.02
Earnings Date Aug 4, 2025

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]

Sector Healthcare
Founded 1980
Employees 28,000
Stock Exchange Deutsche Börse Xetra
Ticker Symbol AMG
Full Company Profile

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.

Financial numbers in USD Financial Statements

News

What Does the Market Think About Amgen?

Amgen's (NYSE: AMGN) short percent of float has risen 11.34% since its last report. The company recently reported that it has 14.75 million shares sold short , which is 2.75% of all regular shares th...

1 day ago - Benzinga

This House of Representative Just Bought Up To $30K In Amgen Stock

A report on July 9, 2025 shows that Representative Cliff Bentz from Oregon purchase stock in Amgen (NASDAQ: AMGN), valued between $2,002 and $30,000. According to the July filing, the transaction occ...

2 days ago - Benzinga

Amgen: How To Find And Own America's Greatest Opportunities

From Amgen's classic double-bottom base in February 1990 until it ultimately topped in the summer of 2000, it increased more than 50 times.

2 days ago - Investor's Business Daily

Final Trades: Amgen, Caterpillar, Honeywell and Freeport-McMoran

The Investment Committee give you their top stocks to watch for the second half.

10 days ago - CNBC Television

Final Trades: Amgen, Caterpillar, Honeywell and Freeport-McMoran

The Investment Committee give you their top stocks to watch for the second half.

10 days ago - CNBC

Why Amgen Stock Popped by 4% Today

11 days ago - The Motley Fool

Flow of funds moves into Dow and small cap stocks.

The market rotated out of the large-cap tech stocks today. Markets got a little spooked by better than expected JOLT job openings and the realization that July is probably not a month for a rate cut. ...

11 days ago - Forexlive

FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls

Argenx SE (NASDAQ: ARGX) stock is trading lower on Monday after the U.S. Food and Drug Administration (FDA) signaled serious risks/safety identified by the reporting system for Vyvgart Hytrulo (efgar...

12 days ago - Benzinga

Amgen's gastric cancer drug meets late-stage trial goal

Amgen said on Monday its experimental cancer therapy, when combined with chemotherapy, met the main goal in a late-stage trial.

12 days ago - Reuters

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER

At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone THOUSAND OAKS, Calif. , June 30, 202...

12 days ago - PRNewsWire

Before this week Amgen hasn't been able to generate excitement for its GLP-1, says Jim Cramer

'Mad Money' host Jim Cramer looks into stock movement connected to Amgen's GLP-1 offerings.

17 days ago - CNBC

Healthy Returns: New weight loss drug data show Eli Lilly is gaining ground

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.

17 days ago - CNBC

Analyst Views Mixed As Amgen's Weight Loss/Diabetes Drug MariTide Shows Promise But Has Dose Issues

Amgen Inc (NASDAQ: AMGN) announced on Monday the full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcu...

18 days ago - Benzinga

Analyst Views Mixed As Amgen's Weight Loss/Diabetes Drug MariTide Shows Promise But Has Dose Issues

Amgen Inc AMGN announced on Monday the full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously a...

18 days ago - Benzinga

What's Happening With Amgen Stock?

Amgen stock (NASDAQ:AMGN) fell 6% on Monday, June 23, 2025, after mid-stage clinical trial results for its long-acting experimental obesity drug, MariTide, revealed a need for a low starting dose to m...

18 days ago - Forbes

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.

19 days ago - CNBC Television

Amgen (AMGN) Stock Falls After Mixed MariTide Trial Update

Amgen shares are trading lower Monday afternoon. ... Full story available on Benzinga.com

19 days ago - Benzinga

Amgen Shares Fall on Weight-Loss Drug Tummy Troubles

At the highest dosage of MariTide, 27% of patients stopped the drug due to a gastrointestinal adverse event.

19 days ago - Barrons

Low start dose of Amgen experimental weight-loss drug limits side effects

People started on a low dose of Amgen's long-acting experimental obesity drug MariTide lost as much weight as those given high doses but with milder side effects, according to full results of a mid-st...

19 days ago - Reuters

RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS

MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant Cardiometabolic Improvement...

19 days ago - PRNewsWire